Isofol Medical AB (publ) (STO:ISOFOL)

Market Cap	244.21M +2.9%
Revenue (ttm)	n/a
Net Income	-56.63M
EPS	-0.19
Shares Out	320.49M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	453,771
Open	0.7600
Previous Close	0.7680
Day's Range	0.7220 - 0.7790
52-Week Range	0.5515 - 0.9900
Beta	1.02
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About Isofol Medical AB

Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in 2008 and is based in Gothenburg, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 7
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ISOFOL

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 2, 2026

Data Sources Report a data error